Empowering Discovery and Development of Bispecific ADCs With a Common Light Chain Antibody Library and a Novel Linker/Payload_Biocytogen Pharmaceuticals (Beijing) Co., Ltd._Empowering,Discovery,and,Development,of,Bispecific,ADCs,With,a,Common,Light,Chain,Antibody,Library,and,a,Novel,Linker,Payload

Please input keywords

Empowering Discovery and Development of Bispecific ADCs With a Common Light Chain Antibody Library and a Novel Linker/Payload

2024.04.26

Bispecific ADCs (bsADCs) are a growing trend in the ADC field, offering improved efficacy and safety for the treatment of heterogeneous solid tumors.

Designing bsADCs requires careful selection of targets, and is not without challenges, including the ability to efficiently screen and assemble bispecific antibodies (bsAbs) for further conjugation. To facilitate bsADC development, Biocytogen established a bsADC platform, which harnesses:

● a fully human common light chain antibody discovery platform RenLite^®,

● an antibody library targeting tumor associated antigens (TAAs), and

● a novel proprietary linker/payload system BLD1102 consisting of a super hydrophilic linker and a potent topoisomerase I inhibitor (TOP1i) payload.

In this webinar, Dr. W. Frank An will discuss the current landscape of bsADCs as a novel therapeutic modality, and provide an introduction to Biocytogen’s bsADC platform, highlighting recent progress of several of the company’s bsADC assets.

Prev:Maximize Your Drug Design Poss...

Next:None